Boston Scientific to Acquire Nalu Medical to Expand Neuromodulation Portfolio

Boston Scientific has agreed to acquire Nalu Medical, the developer of an implantable neurostimulation system for chronic peripheral nerve pain, in a deal valuing the company at $600 million. Boston Scientific, an investor in Nalu since 2017, will pay $533 million for the remaining equity it does not already own. Analysts view the acquisition as part of Boston Scientific’s strategy of expanding through targeted tuck-in deals.

Nalu’s system delivers electrical impulses via an implantable generator to disrupt pain signals before they reach the brain. The FDA-cleared treatment targets pain in areas such as the shoulder, lower back, and knee.

The acquisition complements Boston Scientific’s interventional pain offerings, including spinal cord stimulation, basivertebral nerve ablation, and radiofrequency ablation. Nalu is projected to generate over $60 million in sales in 2025, with growth of 25% expected in 2026. The deal is anticipated to close in the first half of 2026 and gradually contribute to earnings.

20-10-2025